{"title":"勃林格殷格翰:在肿瘤和糖尿病领域取得进展","authors":"","doi":"10.1002/fps.72","DOIUrl":null,"url":null,"abstract":"<p><b>This series of company profiles looks at some of the major players in the UK pharmaceutical industry, their current areas of expertise, and forthcoming products and initiatives that will have an impact on therapeutics and prescribing in the near future. In this article we provide an overview of Boehringer Ingelheim and its current portfolio, and look at its pipeline of new drugs and areas of research interest.</b></p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"11 3","pages":"22-23"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.72","citationCount":"0","resultStr":"{\"title\":\"Boehringer Ingelheim: advances in oncology and diabetes\",\"authors\":\"\",\"doi\":\"10.1002/fps.72\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><b>This series of company profiles looks at some of the major players in the UK pharmaceutical industry, their current areas of expertise, and forthcoming products and initiatives that will have an impact on therapeutics and prescribing in the near future. In this article we provide an overview of Boehringer Ingelheim and its current portfolio, and look at its pipeline of new drugs and areas of research interest.</b></p>\",\"PeriodicalId\":100566,\"journal\":{\"name\":\"Future Prescriber\",\"volume\":\"11 3\",\"pages\":\"22-23\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-01-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/fps.72\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/fps.72\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.72","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Boehringer Ingelheim: advances in oncology and diabetes
This series of company profiles looks at some of the major players in the UK pharmaceutical industry, their current areas of expertise, and forthcoming products and initiatives that will have an impact on therapeutics and prescribing in the near future. In this article we provide an overview of Boehringer Ingelheim and its current portfolio, and look at its pipeline of new drugs and areas of research interest.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
